GuidelineHaematologica2017
Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO).
Guideline in Haematologica, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.
- Pooled it
- CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies.Blood cancer journal · 2018Trial
- Clinical, Biological, and Treatment-Related Predictors of Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma: A Retrospective Cohort Study.Journal of clinical medicine · 2026Article
- Diffuse large B-cell lymphoma in the new era: prognostic tools for mapping risk.Annals of hematology · 2025Review
- Genomic risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma.Blood research · 2025Article
- Central Nervous System Manifestations of Cutaneous Lymphomas.Current neurology and neuroscience reports · 2025Review
- Article
- Cerebrospinal fluid IL-6 and IL-10 as promising diagnostic and therapeutic prognostic biomarkers for secondary central nervous system lymphoma.BMC cancer · 2024Article
- A European consensus recommendation on the management of delayed methotrexate elimination: supportive measures, leucovorin rescue and glucarpidase treatment.Journal of cancer research and clinical oncology · 2024Review
- Article
- Relapsed isolated CNS lymphoma treated with radiotherapy and intrathecal methotrexate followed by high-dose intravenous methotrexate, rituximab, and temozolomide: A case report.Clinical case reports · 2024Article
- Recent updates on central nervous system prophylaxis in patients with high-risk diffuse large B-cell lymphoma.Experimental hematology & oncology · 2024Review
- A Biphasic Presentation of Diffuse Large B-cell Lymphoma Metastasis to the Hypothalamus-pituitary Axis: A Case Report and Literature Review.Journal of community hospital internal medicine perspectives · 2024Article
- Article
- Article
- Intelligent Diagnosis and Analysis of Brain Lymphoma Based on DSC Imaging Features.Computational intelligence and neuroscience · 2022Article
- Impact of Central Nervous System International Prognostic Index on the Treatment of Diffuse Large B Cell Lymphoma.Cureus · 2021Article
- Leptomeningeal relapse in primary cutaneous DLBCL: Implications for a prophylactic CNS therapy.Cancer reports (Hoboken, N.J.) · 2021Article
- Aggregative Perivascular Tumor Cell Growth Pattern of Primary Central Nervous System Lymphomas Is Associated with Hypoxia-Related Endoplasmic Reticulum Stress.Journal of Cancer · 2021Article
- Biological Features and Prognostic Impact of Bone Marrow Infiltration in Patients with Diffuse Large B-Cell Lymphoma.Cancers · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 9 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diffuse large B-cell lymphoma patients have a 5% overall risk of central nervous system events (relapse or progression), which account for high morbidity and frequently fatal outcomes, THERAPY:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.